
Shelby M. King, Timothy R. Smith, J. William Higgins, Celina R. Nino, Alice E. Chen, Sharon C. Presnell, and Deborah G. Nguyen | Organovo, 6275 Nancy Ridge Drive Suite 110, San Diego, CA 92121

Introduction

- The kidney proximal tubule (PT) is a primary site of nephrotoxicity and resulting drug attrition in the development pipeline.
- Using Organovo's proprietary bioprinting platform, we have developed a fully-human *in vitro* model of the PT to potentially enable more accurate prediction of tissue-level clinical outcomes.
- ExVive[™] Human Kidney Tissue is created in a standard 24-well Transwell[®] plate by spatially-controlled deposition of cell aggregates in the absence of exogenous scaffold. Tissues are composed of an interstitial layer of renal fibroblasts and endothelial cells supporting a monolayer of human primary PT epithelial cells.



Renal Transporter Expression and Function





Table 1 and Figure 4: ExVive Human Kidney Tissue retains renal transporter expression over time in culture. Table 1, Tissues were assessed for expression of renal transporters by quantitative RT-PCR over time in culture. Data shown is the fold change of relative quantity (RQ; normalized to cytokeratin 18 (CK18) and GAPDH) versus Day 3. BLQ, below limit of quantitation. A and B, Tissues cultured for 14 days were stained for P-gp or SGLT2 localization to the apical membrane of the PT epithelium in 3D bioprinted tissues.

Cisplatin-induced nephrotoxicity



Wen et al., Am J Path 2014: 184 (5).

Figure 7: Schematic of mechanisms of cisplatin nephrotoxicity. Cisplatin can be actively transported into the proximal tubule epithelium by the uptake transporters CTR1 and OCT2, where it can become concentrated in the epithelium and available for biotransformation. Reactive intermediates can induce intracellular damage through generation of reactive oxygen species. Cisplatin or its detoxified glutathione conjugate can be effluxed from the epithelium by the actions of MATE1 and MRP2.


A 3D Bioprinted Model of the Renal Proximal Tubule for Evaluation of Drug-Induced Nephrotoxicity


duced Nephrotoxicity Organ VO®

Abstract No. 832 Poster No. P19-018


Figure 1: Characterization of ExVive Human Kidney Tissue.


A, Schematic of 3D PT tissues comprising an interstitial layer of renal fibroblasts and endothelial cells supporting a polarized epithelial monolayer in standard Transwell® format. **B**, Bioprinted tissues are highly reproducible from well to well. **C**, H&E. **D**, Masson's trichrome stain for collagen (blue). **E**, CD31 staining for endothelial cell networks. **F**, Cytokeratin 18 staining for epithelial cells. **G**, E-cadherin staining (green) for junctions between epithelial cells and collagen IV staining (red) for basement membrane (arrows). **H**, Basolateral localization of Na⁺K⁺ATPase.














Figure 2: ExVive Human Kidney Tissue exhibits barrier function consistent with observed values for the *in vivo* PT. A, TEER values for 3D bioprinted kidney tissues measured in an Ussing chamber and compared to historical values. **B**, Passive permeability measurements following directional transport of Lucifer yellow. Dotted line indicates a P_{app} measurement of 1x10⁻⁶ cm/s, as observed for monolayer cultures.





Figure 5: ExVive Human Kidney Tissue demonstrates retention of rhodamine 123 following inhibition of P-gp-mediated efflux. A, Tissues were loaded with the fluorescent substrate rhodamine 123 (R123; 1 μ M) in the presence or absence of the P-gp inhibitor zosuquidar (5 μ M). Images were taken at the same exposure time for comparison. B, Fluorescence intensity of individual epithelial cells was quantified in Image J following area and background correction. * indicates *P*<0.05 between groups.






Figure 8: Toxic response of ExVive Human Kidney Tissue to cisplatin is rescued by the OCT2 inhibitor cimetidine. A, Tissues were dosed daily for 7 days and assessed for overall tissue metabolic activity by alamarBlue[®] assay. B, Epithelial function was measured by GGT activity. C and D, H&E shows flattening of epithelial cells in response to Cisplatin, rescued in part by Cimetidine co-treatment. PCNA (green) shows proliferation of epithelial cells in response to damage (white arrows).




Figure 9: Release of neutrophil gelatinaseassociated lipocalin (NGAL) or clusterin into media as biomarkers of kidney injury following 7 days of Cisplatin treatment (Cis).

Figure 3: ExVive Human Kidney Tissue demonstrates gamma glutamyl transferase (GGT) activity for at least 30 days in culture. A, Schematic of the role of GGT activity at the apical membrane of PT epithelial cells for glutathione homeostasis and xenobiotic detoxification. B, GGT activity measured over time for 3D bioprinted tissues (blue) or 3D bioprinted interstitial tissues lacking epithelium (red). SGLT2 Inhibition — a novel strategy for diabetes treatment Edward C. Chao & Robert R. Henry Nature Reviews Drug Discovery 9, 551-559 (July 2010)

Figure 6: ExVive Human Kidney Tissue demonstrates SGLT2mediated uptake of the glucose analog 2-deoxyglucose (2-DG). A, Schematic showing localization and function of the Na⁺/Glucose co-transporter at the apical surface of PT epithelial cells. **B**, 3D bioprinted tissues were starved overnight prior to stimulation with 1 μ M insulin or 1 μ M insulin plus the SGLT2 inhibitor canagliflozin (500 μ M). Tissues were then loaded with 2-DG, homogenized, and assessed for 2-DG retention by colorimetric assay. * indicated *P*<0.05 between groups.

Summary

- ExVive Human Kidney Tissue recapitulated key aspects of the physiology of the PT for at least 30 days in culture, including GGT activity, barrier function, and expression and function of renal transporters.
- The role of OCT2-mediated uptake and concentration of the nephrotoxin cisplatin in PT epithelial cells was confirmed in the 3D tissues histologically and biochemically.
- Together, these results support the use of this novel human 3D tissue model of the PT for assessment of human renal toxicity over extended time in culture.

Safe Harbor Statement

Any statements contained in this report and presentations that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's products and technology; the expected benefits and efficacy of the Company's products and technology; the expected benefits and efficacy of the Company's products, and the risks related to the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the SEC on November 27, 2013, its report on Form 10-Q filed February 6, 2014 and its transition report on Form 10-KT filed with the SEC on May 24, 2013 and our other filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this Current Report. These cautionary statements should be considered with any written or oral forward-looking statements that we may issue in the future. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to cenform these statements to cenfor